Shares of Zura Bio Limited (NASDAQ:ZURA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $17.00.
ZURA has been the topic of several recent analyst reports. Wedbush lifted their price target on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. William Blair initiated coverage on Zura Bio in a research report on Wednesday, July 8th. They issued an “outperform” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, October 2nd. Guggenheim raised their price objective on shares of Zura Bio from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen raised shares of Zura Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st.
Check Out Our Latest Analysis on Zura Bio
Institutional Trading of Zura Bio
Zura Bio Stock Performance
NASDAQ ZURA opened at $4.00 on Tuesday. Zura Bio has a twelve month low of $3.15 and a twelve month high of $7.44. The stock has a market capitalization of $383.32 million, a PE ratio of -3.54 and a beta of 0.01. The stock has a 50-day simple moving average of $5.16 and a 200 day simple moving average of $5.03.
Zura Bio (NASDAQ:ZURA – Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share for the quarter. As a group, equities research analysts forecast that Zura Bio will post -0.81 EPS for the current fiscal year.
About Zura Bio
Zura Bio, Inc is a clinical-stage biotechnology company focused on developing medicines for chronic immune-mediated diseases. The company’s research programs are designed to address conditions in which abnormal immune responses contribute to inflammation and tissue damage.
Zura Bio is advancing a pipeline of investigational antibody-based therapies for diseases including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and systemic sclerosis. Its programs target biological pathways involved in inflammation, with the goal of developing treatments for patients who may not respond adequately to existing therapies.
Further Reading
- Five stocks we like better than Zura Bio
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.
